FDA Launches Neuroscience Nexus to Accelerate Alzheimer's Prevention

The FDA has launched the Neuroscience Advancement and Innovation Nexus (NAIN) as a new agency-wide program to strengthen science and regulation for brain and nervous system conditions. The initiative, announced alongside a focus on the Alzheimer's Prevention Accelerator, aims to speed up medical product development for a range of neurological and psychiatric disorders.

NAIN will coordinate expertise from the FDA's Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, and Center for Devices and Radiological Health. This cross-center collaboration is designed to tackle complex scientific questions that span traditional regulatory boundaries. Reviews and decisions on individual product submissions will remain with the appropriate existing FDA center; NAIN is a coordination initiative, not a replacement approval process.

Focus on Alzheimer's Prevention

NAIN's inaugural initiative is the Alzheimer's Prevention Accelerator, focused on delaying or preventing Alzheimer's disease. This program will explore innovative approaches to clinical trials for Alzheimer's prevention, emphasizing trial populations, stage-appropriate endpoints, and evidentiary approaches for demonstrating prevention or delay of cognitive decline.

The first initiative under NAIN is the Alzheimer’s Prevention Accelerator, which will examine how clinical trials can better evaluate therapies to prevent or delay cognitive decline. It will focus on challenges in designing prevention and early-intervention trials, including selecting suitable participants, choosing appropriate endpoints, and determining evidence of meaningful cognitive delay. These trial challenges are especially difficult because symptoms may take years to emerge.

Cross-Center Coordination

NAIN connects FDA's drug, biologics, and device centers to tackle neuroscience challenges that span traditional regulatory boundaries. The program covers neurological and psychiatric conditions, substance use disorders, and pain, and will engage researchers, companies, and patient communities. Acting FDA Commissioner Kyle Diamantas, J.D., stated that NAIN reflects the FDA's commitment to keeping pace with rapid advances in neuroscience.

Broad Regulatory Scope

The program addresses multiple brain and nervous system conditions including psychiatric disorders, substance use, and pain, without replacing existing approval processes. NAIN will engage patients, caregivers, researchers, industry, public-private partnerships, and other government agencies. The initiative supports the National Alzheimer’s Project Act (NAPA), the federal government's comprehensive roadmap for coordinated action on Alzheimer's and related dementias.

The announcement follows the FDA’s Expedited Investigational New Drug Pilot Program, announced in September, which aims to improve preparation and review of first-in-human study applications. Both initiatives reflect the agency’s wider emphasis on improving evaluation of emerging medical technologies without eliminating existing regulatory oversight. The FDA will connect specialists from drug, biologics, and device centers to tackle scientific questions spanning regulatory boundaries.